Home
AXSM
AXSM News

Latest Axsome Therapeutics Inc. (AXSM) News on April 2, 2025

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

GlobeNewswire

a day ago

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.

Investor's Business Daily

8 days ago

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

GlobeNewswire

8 days ago

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?

Zacks

13 days ago

Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?

Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025?

Insider Monkey

19 days ago

Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025?

AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

Zacks

a month ago

AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

GlobeNewswire

a month ago

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

GlobeNewswire

a month ago

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025

Insider Monkey

a month ago

Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025

Axsome Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

a month ago

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

a month ago

Axsome Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

Benzinga

a month ago

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

GlobeNewswire

a month ago

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025

Insider Monkey

a month ago

Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025

These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

Investor's Business Daily

a month ago

These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025

Insider Monkey

a month ago

Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025

GuruFocus.com

a month ago

Axsome Therapeutics Inc (AXSM) Q4 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...

Thomson Reuters StreetEvents

a month ago

Q4 2024 Axsome Therapeutics Inc Earnings Call

Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript

Motley Fool

a month ago

Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire

a month ago

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?

Motley Fool

a month ago

This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?

Why Axsome Therapeutics (AXSM) Is Advancing Today

Insider Monkey

2 months ago

Why Axsome Therapeutics (AXSM) Is Advancing Today

Why Axsome Therapeutics Stock Is Soaring Today

Motley Fool

2 months ago

Why Axsome Therapeutics Stock Is Soaring Today

Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva

Zacks

2 months ago

Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva

Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?

Zacks

2 months ago

Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?

Why Axsome Therapeutics Stock Is Skyrocketing Today

Motley Fool

2 months ago

Why Axsome Therapeutics Stock Is Skyrocketing Today

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

Benzinga

2 months ago

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

GlobeNewswire

2 months ago

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises

Zacks

2 months ago

Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

GlobeNewswire

2 months ago

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

GlobeNewswire

2 months ago

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

GlobeNewswire

2 months ago

Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Investor's Business Daily

3 months ago

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

GlobeNewswire

3 months ago

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook

Simply Wall St.

3 months ago

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

Benzinga

3 months ago

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation

Investor's Business Daily

3 months ago

Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

GlobeNewswire

3 months ago

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report?

Zacks

4 months ago

Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report?

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

Benzinga

4 months ago

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock ascends 5.5% this past week

Simply Wall St.

4 months ago

Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock ascends 5.5% this past week

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

GlobeNewswire

4 months ago

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up

Zacks

5 months ago

Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up

Thomson Reuters StreetEvents

5 months ago

Q3 2024 Axsome Therapeutics Inc Earnings Call

Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript

Motley Fool

5 months ago

Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript

GuruFocus.com

5 months ago

Axsome Hits 52-Week High After Surging Nearly 5%--FDA Milestones Could Fuel Even Bigger Gains

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

5 months ago

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

GlobeNewswire

5 months ago

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

Zacks

5 months ago

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

GlobeNewswire

5 months ago

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

3 Bargain Stocks to Buy in a Market That's Priced for Perfection

Motley Fool

5 months ago

3 Bargain Stocks to Buy in a Market That's Priced for Perfection

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

GlobeNewswire

6 months ago

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

1 Under-the-Radar Biotech Stock to Buy and Hold

Motley Fool

6 months ago

1 Under-the-Radar Biotech Stock to Buy and Hold

Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024

GlobeNewswire

6 months ago

Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024

FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

Zacks

7 months ago

FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

GlobeNewswire

7 months ago

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics to Participate in Investor Conferences in September

GlobeNewswire

7 months ago

Axsome Therapeutics to Participate in Investor Conferences in September

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

GlobeNewswire

7 months ago

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

Jim Cramer Thinks Axsome Therapeutics Inc (NASDAQ:AXSM) Stock Can Double

Insider Monkey

8 months ago

Jim Cramer Thinks Axsome Therapeutics Inc (NASDAQ:AXSM) Stock Can Double

Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript

Motley Fool

8 months ago

Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript

Why Axsome Therapeutics Stock Is Sinking Today

Motley Fool

8 months ago

Why Axsome Therapeutics Stock Is Sinking Today

Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates

Zacks

8 months ago

Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

8 months ago

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit

Simply Wall St.

8 months ago

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit

Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics

Zacks

8 months ago

Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics

Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future

Benzinga

8 months ago

Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future

Bull Market and Beyond: 2 Stocks Just Waiting to Soar

Motley Fool

9 months ago

Bull Market and Beyond: 2 Stocks Just Waiting to Soar

Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5

GlobeNewswire

9 months ago

Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5

Investors ignore increasing losses at Axsome Therapeutics (NASDAQ:AXSM) as stock jumps 7.0% this past week

Simply Wall St.

9 months ago

Investors ignore increasing losses at Axsome Therapeutics (NASDAQ:AXSM) as stock jumps 7.0% this past week

Why Axsome Therapeutics Stock Is Sinking Today

Motley Fool

10 months ago

Why Axsome Therapeutics Stock Is Sinking Today

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

GlobeNewswire

10 months ago

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

GlobeNewswire

10 months ago

Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month

GlobeNewswire

10 months ago

Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month

Axsome Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

10 months ago

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024

GlobeNewswire

10 months ago

Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024

Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting

GlobeNewswire

10 months ago

Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting

3 Monster Stocks in the Making You Can Buy Right Now

Motley Fool

10 months ago

3 Monster Stocks in the Making You Can Buy Right Now

15 Most Depressed States in the US

Insider Monkey

a year ago

15 Most Depressed States in the US

Prediction: These 2 Growth Stocks Could Triple By 2030

Motley Fool

a year ago

Prediction: These 2 Growth Stocks Could Triple By 2030

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Simply Wall St.

a year ago

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Axsome Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

a year ago

Axsome Therapeutics to Present at Upcoming Investor Conferences

Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates

Zacks

a year ago

Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript

GuruFocus.com

a year ago

Axsome Therapeutics Inc (AXSM) (Q1 2024) Earnings Call Transcript Highlights: Soaring Revenues ...

Thomson Reuters StreetEvents

a year ago

Q1 2024 Axsome Therapeutics Inc Earnings Call

Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript

Motley Fool

a year ago

Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?

Zacks

a year ago

Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?

Axsome Therapeutics Recognizes May as Mental Health Awareness Month

GlobeNewswire

a year ago

Axsome Therapeutics Recognizes May as Mental Health Awareness Month

15 Most Black States in the US

Insider Monkey

a year ago

15 Most Black States in the US

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

GlobeNewswire

a year ago

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

GlobeNewswire

a year ago

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study

Zacks

a year ago

Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study

Insider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM)

GuruFocus.com

a year ago

Insider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM)

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

GlobeNewswire

a year ago

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

30 Countries with the Lowest Depression Rates

Insider Monkey

a year ago

30 Countries with the Lowest Depression Rates

20 Cloudiest Cities in the U.S., Ranked

Insider Monkey

a year ago

20 Cloudiest Cities in the U.S., Ranked

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

GlobeNewswire

a year ago

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

GlobeNewswire

a year ago

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Motley Fool

a year ago

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Share on Social Networks: